A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

Magenkarzinom – Was gibt’s Neues?

Diagnose von Intraduktal papillär-muzinöse Neoplasien (IPMN) – Bestandsaufnahme der Versorgungsrealität an einem deutschen Zentrum

Mehrwert von EUS gesteuerten Fein-Nadel-Biopsien (FNB) gegenüber FN-Aspiration (FNA) von unklaren Läsionen im Gastrointestinal (GI)-Trakt